Short-term efficacy of ORS formulation and propranolol regimen in children with POTS.


Journal

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
ISSN: 1769-664X
Titre abrégé: Arch Pediatr
Pays: France
ID NLM: 9421356

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 26 02 2020
revised: 09 04 2020
accepted: 01 06 2020
pubmed: 12 7 2020
medline: 6 7 2021
entrez: 12 7 2020
Statut: ppublish

Résumé

To evaluate the short-term effectiveness of reduced-osmolarity oral rehydration salt formulation (ORS) and propranolol in children diagnosed with postural orthostatic tachycardia syndrome (POTS) in head-up tilt testing (HUTT). Children were admitted with symptoms of orthostatic intolerance (OI) occurring in a standing position and disappearing in the supine position. Patients with heart rate increments of ≥40bpm and symptoms of OI constituted the pediatric POTS group in HUTT. A total of 70 pediatric patients with POTS were included in the study. POTS patients were divided into two groups based on whether they were prescribed reduced-osmolarity ORS and propranolol or not. The study group comprised patients on a regimen of reduced-osmolarity ORS and propranolol (n=34), while the control group comprised patients who were not prescribed any medication (n=36). The frequency of symptoms and standardized symptom scores were analyzed before and after 3 months of treatment in both groups. The post-treatment frequency of syncopal attacks was significantly reduced in both groups (P<0.01 for both groups), but the post-treatment standardized symptom scores were significantly reduced in the pediatric study group compared with the control group (P<0.01). The frequency of syncopal attacks was significantly reduced and the symptom scores for OI were improved in the study group. The improvement in OI symptom scores was better in the treatment group than in the control group. The control group symptoms persisted and caused extreme difficulty in their daily activities. In view of its clinical efficacy, we strongly advocate the use of combined treatment of reduced-osmolarity ORS and low-dose propranolol in pediatric patients with POTS.

Sections du résumé

BACKGROUND BACKGROUND
To evaluate the short-term effectiveness of reduced-osmolarity oral rehydration salt formulation (ORS) and propranolol in children diagnosed with postural orthostatic tachycardia syndrome (POTS) in head-up tilt testing (HUTT).
METHODS METHODS
Children were admitted with symptoms of orthostatic intolerance (OI) occurring in a standing position and disappearing in the supine position. Patients with heart rate increments of ≥40bpm and symptoms of OI constituted the pediatric POTS group in HUTT. A total of 70 pediatric patients with POTS were included in the study. POTS patients were divided into two groups based on whether they were prescribed reduced-osmolarity ORS and propranolol or not. The study group comprised patients on a regimen of reduced-osmolarity ORS and propranolol (n=34), while the control group comprised patients who were not prescribed any medication (n=36). The frequency of symptoms and standardized symptom scores were analyzed before and after 3 months of treatment in both groups.
RESULTS RESULTS
The post-treatment frequency of syncopal attacks was significantly reduced in both groups (P<0.01 for both groups), but the post-treatment standardized symptom scores were significantly reduced in the pediatric study group compared with the control group (P<0.01).
CONCLUSION CONCLUSIONS
The frequency of syncopal attacks was significantly reduced and the symptom scores for OI were improved in the study group. The improvement in OI symptom scores was better in the treatment group than in the control group. The control group symptoms persisted and caused extreme difficulty in their daily activities. In view of its clinical efficacy, we strongly advocate the use of combined treatment of reduced-osmolarity ORS and low-dose propranolol in pediatric patients with POTS.

Identifiants

pubmed: 32651146
pii: S0929-693X(20)30135-4
doi: 10.1016/j.arcped.2020.06.001
pii:
doi:

Substances chimiques

Adrenergic beta-Antagonists 0
Electrolytes 0
Propranolol 9Y8NXQ24VQ
Rehydration Solutions 0

Types de publication

Controlled Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

328-332

Informations de copyright

Copyright © 2020 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Yilmaz Yozgat (Y)

Department of Pediatric Cardiology, Bezmialem Vakif University, Istanbul, Turkey.

Hafize Otcu Temur (HO)

Department of Radiology, Bezmialem Vakif University, Istanbul, Turkey.

Senay Coban (S)

Department of Pediatric Cardiology, Istanbul Medipol University, Istanbul, Turkey.

Taliha Oner (T)

Department of Pediatric Cardiology, Izmir Dr. Behcet Uz Children's Hospital, Izmir, Turkey.

Utku Karaarslan (U)

Department of Pediatrics, Izmir Dr. Behcet Uz Children's Hospital, Izmir, Turkey.

Can Yilmaz Yozgat (CY)

Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey. Electronic address: yozgatyilmaz@gmail.com.

Cem Karadeniz (C)

Department of Pediatric Cardiology, Izmir Dr. Behcet Uz Children's Hospital, Izmir, Turkey.

Serap Nur Ergor (SN)

Department of Neonatology, Bezmialem Vakif University, Istanbul, Turkey.

Ufuk Erenberk (U)

Department of Pediatrics, Bezmialem Vakif University, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH